Literature DB >> 11061055

Monotherapy with amlodipine or atenolol versus their combination in stable angina pectoris.

S K Pehrsson1, I Ringqvist, S Ekdahl, B W Karlson, G Ulvenstam, S Persson.   

Abstract

BACKGROUND: The basic cause of angina pectoris is imbalance between the metabolic needs of the myocardium and the capacity of the coronary circulation to deliver sufficient oxygenated blood to satisfy these needs. HYPOTHESIS: The study was undertaken to evaluate whether the effect of combined amlodipine and atenolol therapy on patients with stable angina pectoris and with ST-depression during exercise testing and 48-h ambulatory electrocardiographic monitoring is superior to that of either agent given alone.
METHODS: Patients with stable angina pectoris and ST depression during exercise and ambulatory monitoring were randomized to receive amlodipine (n = 116) or atenolol (n = 116), or both (n = 119). All patients were also treated with short- and long-acting nitrates. The design was a double-blind, randomized, triple-arm parallel group study with 10 weeks of administration of the test medication.
RESULTS: In terms of time to onset of ST depression > 1 mm, time to onset of angina, total exercise time, maximum achieved workload, and peak intensity of angina, amlodipine and atenolol alone were as effective as their combination. During ambulatory monitoring, atenolol was more effective than amlodipine regarding total time and number of ST-depression episodes, and as effective as the combined drugs.
CONCLUSION: For individual patients with stable angina pectoris, combination of a beta blocker with a calcium antagonist is not necessarily more effective than either drug given alone.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11061055      PMCID: PMC6654955          DOI: 10.1002/clc.4960231014

Source DB:  PubMed          Journal:  Clin Cardiol        ISSN: 0160-9289            Impact factor:   2.882


  3 in total

1.  Antianginal efficacy and safety of ivabradine compared with amlodipine in patients with stable effort angina pectoris: a 3-month randomised, double-blind, multicentre, noninferiority trial.

Authors:  Witold Ruzyllo; Michal Tendera; Ian Ford; Kim M Fox
Journal:  Drugs       Date:  2007       Impact factor: 9.546

2.  Efficacy of the long-acting nitro vasodilator pentaerithrityl tetranitrate in patients with chronic stable angina pectoris receiving anti-anginal background therapy with beta-blockers: a 12-week, randomized, double-blind, placebo-controlled trial.

Authors:  Thomas Münzel; Thomas Meinertz; Ulrich Tebbe; Heinrich Theodor Schneider; Dirk Stalleicken; Manfred Wargenau; Tommaso Gori; Ingrid Klingmann
Journal:  Eur Heart J       Date:  2013-09-26       Impact factor: 29.983

3.  Efficacy of the I(f) current inhibitor ivabradine in patients with chronic stable angina receiving beta-blocker therapy: a 4-month, randomized, placebo-controlled trial.

Authors:  Jean-Claude Tardif; Piotr Ponikowski; Thomas Kahan
Journal:  Eur Heart J       Date:  2009-01-09       Impact factor: 29.983

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.